Hostname: page-component-5c6d5d7d68-wbk2r Total loading time: 0 Render date: 2024-08-15T01:45:43.875Z Has data issue: false hasContentIssue false
  • English
  • Français

The treatment of certain experimental anaerobic infections with sulphapyridine and with immune sera and the problem of synergic action

Published online by Cambridge University Press:  15 May 2009

D. W. Henderson  and
P. A. Gorer
D. W. Henderson
Affiliation:
Lister Institute, Serum Department, Elstree, Herts
P. A. Gorer
Affiliation:
Lister Institute, Serum Department, Elstree, Herts
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

1. Sulphapyridine is an efficient prophylactic or therapeutic agent against intradermal infection with the strain of Vibrion septique selected for test, whereas, in intramuscular infection the drug is unreliable and saves only a relatively small proportion of animals.

2. The strain of Cl. welchii (type A) selected for test is not insusceptible to the action of sulphapyridine. A significant degree of protection against intradermal infection may be obtained however, only when a prophylactic dose of the drug is given. The drug is apparently without action against intramuscular infection with this strain.

3. Under the particular experimental conditions sulphanilamide is much less effective than sulphapyridine against infection with either V. septique or Cl. welchii.

4. There is no evidence that sulphapyridine given per os neutralizes the toxins of V. septique or Cl. welchii injected intravenously.

5. It is possible to control infection with V. septique by antitoxin or antibacterial serum given at a time when sulphapyridine is of little use. Cl. welchii antitoxin has a marked therapeutic effect in infection with this strain of the organism but sulphapyridine given only after infection is apparently without action on the course of the disease.

6. In intradermal infection with V. septique the combined action of sulpha-pyridine and antitoxin or of sulphapyridine and antibacterial serum effects a saving in life much greater than would be expected if a mere summation effect was in question. A similar effect was observed in intramuscular infection provided the administration of the drug was sufficiently prolonged. No such synergic effect is produced by the combined action of antitoxic and antibacterial serum.

7. In Cl. welchii infection the combined action of antitoxin and sulpha-pyridine produces a noticeable synergic effect but the evidence on this point is less clearly defined.

8. The pathogenesis of infection with spore-bearing anaerobes is discussed in relation to prophylaxis or therapy with chemotherapeutic agents, antitoxin, antibacterial serum and combinations of such.

9. The statistical aspect of summation effects is briefly considered pending a forthcoming mathematical analysis, by Dr K. Mather, of the figures obtained in experiments on synergic action.

Type
Research Article
Information
Journal of Hygiene , Volume 40 , Issue 3 , May 1940 , pp. 345 - 364
Copyright
Copyright © Cambridge University Press 1940

References

REFERENCES

Buttle, G. A. H. (1939). Brit. med. J. 2, 269.CrossRefGoogle Scholar
Carpenter, C. M. & Barbour, G. M. (1939). Proc. Soc. exp. Biol, N.Y., 41, 354.CrossRefGoogle Scholar
Coleman, G. E. & Gunnison, J. B. (1931). Amer. J. Hyg. 14, 526.Google Scholar
Craddock, S. & Parish, H. J. (1931). Brit. J. exp. Path. 12, 389.Google Scholar
Fildes, P. (1929 a). Brit. J. exp. Path. 10, 151.Google Scholar
Fildes, P. (1929 b). Brit. J. exp. Path. 10, 197.Google Scholar
Fleming, A. (1939). Proc. roy. Soc. Med. 32, 911.CrossRefGoogle Scholar
Henderson, D. W. (1934). Brit. J. exp. Path. 15, 166.Google Scholar
Henderson, D. W. (1935). Brit. J. exp. Path. 16, 393.Google Scholar
Henderson, D. W. (1937). Brit. J. exp. Path. 18, 224.Google Scholar
Long, P. H. & Bliss, E. A. (1937). Canad. med. Ass. J. 37, 457.Google Scholar
Long, P. H. & Bliss, E. A. (1939). Clinical use of Sulphanilamide and Sulphapyridine and Allied Compounds. New York: Macmillan Company.Google Scholar
Mayer, R. L. (1938). Bull. Acad. Méd. 120, 277.Google Scholar
Mayer, R. L. (1939). C.R. Soc. Biol., Paris, 130, 1560.Google Scholar
Robertson, M. & Felix, A. (1930). Brit. J. exp. Path. 11, 14.Google Scholar
Russell, D. S. (1927). Brit. J. exp. Path. 8, 377.Google Scholar
Whitby, L. E. H. (1938). Lancet, 1, 1210.CrossRefGoogle Scholar